A$1.52
1.34% today
Australia, Oct 06, 03:11 am CET
ISIN
AU000000PNV0
Symbol
PNV

PolyNovo Limited Stock price

A$1.50
+0.11 7.94% 1M
+0.40 35.91% 6M
-0.55 26.72% YTD
-1.03 40.67% 1Y
+0.17 12.41% 3Y
-0.76 33.56% 5Y
+1.36 1,007.41% 10Y
+0.88 141.13% 20Y
Australia, Closing price Fri, Oct 03 2025
+0.03 1.70%
ISIN
AU000000PNV0
Symbol
PNV

Key metrics

Basic
Market capitalization
A$1.0b
Enterprise Value
A$999.1m
Net debt
positive
Cash
A$33.6m
Shares outstanding
690.8m
Valuation (TTM | estimate)
P/E
74.8 | 67.7
P/S
8.0 | 6.4
EV/Sales
7.8 | 6.3
EV/FCF
negative
P/B
12.2
Financial Health
Equity Ratio
65.4%
Return on Equity
15.9%
ROCE
7.0%
ROIC
17.2%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
A$127.7m | A$159.0m
EBITDA
A$9.6m | A$19.1m
EBIT
A$6.9m | A$15.3m
Net Income
A$13.2m | A$15.3m
Free Cash Flow
A$-10.8m
Growth (TTM | estimate)
Revenue
22.0% | 24.5%
EBITDA
81.5% | 149.4%
EBIT
122.7% | 207.7%
Net Income
151.1% | 15.4%
Free Cash Flow
-1,464.6%
Margin (TTM | estimate)
Gross
96.6%
EBITDA
7.6% | 12.0%
EBIT
5.4%
Net
10.4% | 9.6%
Free Cash Flow
-8.4%
More
EPS
A$0.0
FCF per Share
A$0.0
Short interest
-
Employees
282
Rev per Employee
A$450.0k
Show more

Is PolyNovo Limited a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

PolyNovo Limited Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a PolyNovo Limited forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a PolyNovo Limited forecast:

Buy
82%
Hold
18%

Financial data from PolyNovo Limited

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
128 128
22% 22%
100%
- Direct Costs 4.31 4.31
21% 21%
3%
123 123
24% 24%
97%
- Selling and Administrative Expenses 105 105
26% 26%
82%
- Research and Development Expense 8.46 8.46
23% 23%
7%
9.64 9.64
82% 82%
8%
- Depreciation and Amortization 2.70 2.70
23% 23%
2%
EBIT (Operating Income) EBIT 6.95 6.95
123% 123%
5%
Net Profit 13 13
151% 151%
10%

In millions AUD.

Don't miss a Thing! We will send you all news about PolyNovo Limited directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Polynovo Ltd. engages in the development of medical devices, utilizing the patented polymer technology NovoSorb. The company is headquartered in Melbourne, Victoria and currently employs 301 full-time employees. Its solutions include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb MTX. NovoSorb BTM is a synthetic, biodegradable and biocompatible device designed to facilitate the dermis to grow within a patented polyurethane matrix when lost through extensive surgery, trauma or burn. NovoSorb BTM is indicated for use in the management of wounds, including partial and full thickness wounds, pressure ulcers, venous and diabetic ulcers, chronic and vascular ulcers, surgical wounds, trauma wounds and draining wounds. Its development program covers breast sling, hernia, and orthopedic applications. NovoSorb MTX is available in a range of sizes to address acute and chronic dermal wounds and is comprised of a 2mm biodegradable foam with no sealing membrane.

Head office Australia
CEO Mr. Raote
Employees 282
Website polynovo.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today